

SYNTHESIS OF SULFAZECIN-TYPE
2-AZETIDINONES WITH
A CARBON SUBSTITUENT
AT THE 4-POSITION

Sir:

As reported in our previous paper,¹⁾ chemical modification of sulfazecin²⁾ at the 3-position significantly enhanced its antibacterial activity; however, further improvement was desired especially in regard to the stability to some β -lactamases. We focused our attention on modifying the unexplored 4-position, and *cis*-1-(2,4-dimethoxybenzyl)-4-methoxycarbonyl-3-phthalimido-2-azetidinone (**1a**) was selected as a starting material, since the methoxycarbonyl group can be convertible into various kinds of other 4-substituents.³⁾ Compound **1a**, first synthesized by GLEASON *et al.*,³⁾ was obtained in 72% yield as colorless needles, mp 172~175°C, by a slightly modified cycloaddition reaction in which the amount of triethylamine was increased to 1.2 molar equivalents. Epimerization⁴⁾ of **1a** with 1,8-diazabicyclo[5.4.0]-7-undecene in benzene gave the *trans* isomer (**1b**), and both **1a** and **1b** were converted into 3-acylamino-1-sulfo derivatives (**6a,b**) (Chart 1). Since the antibacterial

activity of the 3,4-*cis* compound (**6a**) was higher than that of the *trans* isomer (**6b**), and **6a** was very active against *Escherichia coli* T-7, a producer of TEM-1 β -lactamase, we decided to explore further modification of the *cis* series.

Treatment of **4a** with 25~28% ammonia water or 40% aqueous methylamine in tetrahydrofuran (THF) gave 4-carbamoyl- and 4-methylcarbamoyl-2-azetidinones (**7a,b**) respectively. Hydrolysis of **4a** with K_2CO_3 afforded the 4-carboxy compound (**7c**), which was then converted into 4-dimethylcarbamoyl and 4-methoxycarbamoyl derivatives (**7d,e**). Reduction⁵⁾ of **3a** and **4a** with sodium borohydride in THF-water gave alcohols (**8a,b**), from which various 3-amino-4-substituted 2-azetidinones (**9**) were prepared by the conventional methods. For example, compound **9a** was obtained by treating **8a** with chlorosulfonyl isocyanate followed by deprotection (Chart 2). Among the 3-acylamino-1-sulfo derivatives derived from these intermediates in a procedure similar to that of Chart 1, 4-carbamoyl and 4-carbamoyloxymethyl compounds (**11** and **12**) were found to be highly active against Gram-negative bacteria including *Pseudomonas aeruginosa* and some β -lactamase producing strains.

Since ceftazidime has unique antibacterial

Chart 1.





Chart 2.

Table 1. Antibacterial activities^a of AMA-1080 (**21b**), compound **22a** and two reference antibiotics.^b (MIC: $\mu\text{g/ml}$)

Organism	β -Lactamases type	AMA-1080 (21b)	22a	Aztreonam	Ceftazidime
<i>Escherichia coli</i> NIHJ JC-2	—	0.1	0.2	0.1	0.39
<i>E. coli</i> T-7	TEM-1 ^d	0.2	0.39	0.39	0.78
<i>Klebsiella pneumoniae</i> TN 1711 ^c	IV ^e	0.1	0.2	25	0.39
<i>Enterobacter cloacae</i> IFO 12937	Ia ^e	0.78	0.39	3.13	6.25
<i>Serratia marcescens</i> IFO 12648	Ia ^e	0.05	0.2	0.1	0.2
<i>Proteus vulgaris</i> IFO 3988	Ic ^e	0.05	0.2	0.013	0.2
<i>Pseudomonas aeruginosa</i> IFO 3455	Ia ^e	1.56	1.56	3.13	1.56
<i>P. aeruginosa</i> GN 3407	PSE-1 ^d	6.25	6.25	6.25	6.25


^a Activities were determined by the agar dilution method using an inoculum of 10^8 cfu/ml.^b Reference compounds were prepared according to the reported procedure.^c Indole positive.^d Plasmid-mediated β -lactamases.^e Chromosomal β -lactamases (RICHMOND classification).

activity especially against Gram-negative bacteria, we tried* to synthesize new compounds having the analogous acyl groups at the 3-position of **11** and **12**. The acylating agents (**16** and **17**) were

* The independent work of SYKES *et al.*⁶⁾ led to the development of a clinical candidate, aztreonam, having the ceftazidime side-chain.

prepared as shown in Chart 3. To protect the carboxy groups, 4-nitrobenzyl esters were conveniently prepared. Optical resolution of **2a** was carried out by the use of di-(4-toluoyl)-D-tartaric acid to give the (3*S*,4*S*)-3-amino compound (**18**), which was then converted into four sulfazecin-type 2-azetidiones (**21a,b** and **22a,b**)

Chart 3.



(Chart 3). Selective sulfonation at the 1-position of **19a,b** was successfully achieved with sulfur trioxide-pyridine complex in dioxane; after hydrogenolysis the products were isolated as crystalline zwitter ions (**20a,b**)*

As shown in Table 1, AMA-1080 (**21b**) was highly active against Gram-negative bacteria and the protective effect on experimental intraperitoneal infection in mice reflected the *in vitro*

* The absolute structure of **20b** was confirmed by X-ray analysis, and the details will be published elsewhere.

activity. Further evaluation of this compound as a possible clinical candidate is now in progress. Compound **22a** also exhibited good antibacterial activity and high stability to β -lactamases produced by various bacterial species. Chiral syntheses of **21b** and **22a** have been extensively investigated from the practical point of view, and several pathways to prepare the important intermediates (**20a,b**) have been established starting from penicillin, L-tartaric acid and (2*R*,3*R*)-epoxysuccinic acid,⁷⁾ which will be reported elsewhere.

SHOJI KISHIMOTO
MICHUYUKI SENDAI
SHOHEI HASHIGUCHI
MITSUMI TOMIMOTO
YOSHIKI SATOH
TAISUKE MATSUO (deceased)
MASAHIRO KONDO
MICHIIHIKO OCHIAI

Central Research Division,
Takeda Chemical Industries, Ltd.,
Jusohonmachi, Yodogawa-ku,
Osaka 532, Japan

(Received June 24, 1983)

References

- 1) MATSUO, T.; T. SUGAWARA, H. MASUYA, Y. KAWANO, N. NOGUCHI & M. OCHIAI: Synthesis and antibacterial activity of 3-acylamino-2-azetidinone-1-sulfonic acid derivatives. *Chem. Pharm. Bull.* 31: 1874~1884, 1983
- 2) IMADA, A.; K. KITANO, K. KINTAKA, M. MUROI & M. ASAI: Sulfazecin and isosulfazecin, novel β -lactam antibiotics of bacterial origin. *Nature* 289: 590~591, 1981
- 3) GLEASON, J. G.; K. G. HOLDEN & W. F. HUFFMAN (Smith Kline Corp.): 7 β -Acylamino-6 α -H-8-oxo-4-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid derivatives. Ger. Offen. Patent 2,619,458, 1976 [*Chem. Abstr.* 86: 515, 1977]
- 4) BOSE, A.K.; C.S. NARAYANAN & M.S. MANHAS: Epimerization of a *trans*- β -lactam. *J. Chem. Soc., Chem. Commun.* 1970: 975~976, 1970
- 5) HUFFMAN, W. F.; K. G. HOLDEN, T. F. BUCKLEY, III, J. G. GLEASON & L. WU: Nuclear analogues of β -lactam antibiotics. 1. The total synthesis of a 7-oxo-1,3-diazabicyclo[3.2.0]heptane-2-carboxylic acid *via* a versatile monocyclic β -lactam intermediate. *J. Am. Chem. Soc.* 99: 2352~2353, 1977
- 6) SYKES, R. B.; D. P. BONNER, K. BUSH & N. H. GEORGOPAPADAKOU: Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic Gram-negative bacteria. *Antimicrob. Agents Chemother.* 21: 85~92, 1982
- 7) MILLER, M. W.: Derivatives of (-)-*trans*-2,3-epoxysuccinic acid and some of their biological effects. *J. Med. Chem.* 6: 233~237, 1963